Actinium Pharmaceuticals (Delaware) (ATNM) vs Cue Biopharma (CUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Cue Biopharma (CUE) over the past year, losing 21.1% versus a loss of 76.8%. Over five years, ATNM leads with a -85.6% price change compared with -98.9% for CUE. Cue Biopharma is the larger company by market cap ($34.7 million vs $33.0 million), about 1.1 times the size.
Cue Biopharma converts more of its revenue into profit, with a net margin of -96.9% versus -37652.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | CUE |
|---|---|---|
| Share price | $1.05 | $4.15 |
| Market cap | $33.01M | $34.69M |
| 1-day change | -1.87% | -7.78% |
| YTD return | -22.79% | -54.64% |
| 1-year return | -21.05% | -76.75% |
| 5-year return | -85.60% | -98.92% |
| P/E ratio (TTM) | 2.44 | — |
| EPS (TTM) | $0.43 | $-27.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $90.00K | $27.47M |
| Revenue growth (YoY) | — | +195.75% |
| Net income (latest FY) | $-33.89M | $-26.60M |
| Operating margin | -40274.44% | -96.67% |
| Net margin | -37652.22% | -96.85% |
| 52-week high | $1.72 | $45.50 |
| 52-week low | $0.735 | $2.83 |
| Distance from 52-week high | -38.95% | -90.88% |
| Analyst consensus | none | none |
| Avg. price target upside | +242.86% | +2020.48% |
| Average volume | 193.83K | 567.02K |
| Shares outstanding | 31.44M | 8.36M |
| Employees | 27 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed CUE by 55.7 percentage points over the past year.
- Cue Biopharma is more profitable, keeping -96.9 cents of every revenue dollar as net income versus -37652.2 cents for Actinium Pharmaceuticals (Delaware).
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
ATNM vs CUE FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Cue Biopharma?
Cue Biopharma (CUE) is larger, with a market capitalization of $34.69M compared with $33.01M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or CUE?
ATNM returned -21.05% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and Cue Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.